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Abstract
Background: We have previously described the association between rheumatoid arthritis (RA) prevalence and the
two mutY Homolog (E. coli) (MUTYH) SNPs (rs3219463 and rs3219476) among the Taiwanese population. This
present study will aim to elucidate whether the SNPs can alter the expression of EGFR in the progression of RA.
Methods: The cohort study included 368 Taiwan’s Han Chinese RA patients and 364 healthy controls. Blood
samples collected from the participants were analyzed to determine their serum MUTYH levels and to identify
rs3219463 SNP of MUTYH from their genomic DNA.
Results: Our data resulted in a statistically significant difference in genotype frequency distributions at rs3219463
for RA patients and controls (p < 0.0002). Also, the patients with G carrier at rs3219463 were less likely to suffer from
painful joints (p < 0.006) and DAS28 scores (p < 0.003). Furthermore, the increase in serum level of MUTYH was also
observed in RA patients (p < 0.005).
Conclusions: Our study showed that RA is associated with rs3219463 SNP in EGFR gene and an increased serum
level of the MUTYH protein. These findings suggest MUTYH is worthy of further investigation as a therapeutic target
for RA.
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Background
Rheumatoid arthritis (RA) is a chronic systemic inflam-
matory disease characterized by persistent leukocytes
infiltration, suppressed synovial fluid leukocyte apoptosis
and sustained synovial hyperplasia [1–5]. If not properly
treated, chronic joint inflammation can lead to permanent
joint damage, and thus, lead to deformity. Although the
pathophysiological causes of RA are not fully known,
oxidative stress-induced cellular deoxyribonucleic acid
(DNA) damage has been implicated in its pathogenesis
[6–9].
In human cells, oxidative DNA attacks are happening
thousands and millions of times per cell per day [10].
We are concerned that these attacks may lead to
unfavorable genetic alternations. Normal cellular metab-
olism and environmental factors such as radiation and
UV light appear to be the endogenous and exogenous
instigators of DNA damages [10]. For this, the evolution-
ary process has equipped us with sophisticated DNA
repair systems to preserve genetic stability. The major
mechanism that cells use to repair oxidative DNA lesions,
such as 8-oxo-7,8-dihydroguanine (8-oxo-G) and
numerous types of oxidative DNA base damage products,
is known as the base excision repair (BER) system [11, 12].
BER is initiated by DNA glycosylases, which recognize
and remove specific damaged or mispaired bases, forming
AP sites. These AP sites are then cleaved by AP endonu-
cleases to yield a 3' hydroxyl adjacent to a 5' deoxyribose-
phosphate (dRP). The resulting single-strand break can
subsequently be repaired by either short-patch or long-
patch BER [10, 13]. The association of base excision repair
(BER) of oxidative DNA damage and oxidative stress with
RA were described previously [6–9]. Here, we are
interested in the enzymes involved in the BER pathway
and its association with RA.
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mutY Homolog (E. coli) (MUTYH) is a unique DNA
glycosylase that proficiently recognizes and catalyzes the
removal of a mispaired adenine (A) from A:8-oxo-G, a
frequent DNA lesion estimated to emerge around 1000–
7000 times per cell per day [14–16]. Thus MUTYH is a
key factor for giving a way to the supreme BER that
eventually restores the undamaged guanine (G) [17, 18].
Most DNA is packaged in chromosomes within the nu-
cleus (nDNA), but it can also be found in the mitochon-
dria (mtDNA). Both nDNA and mtDNA are essential for
proper cellular functioning; they are needed to flawlessly
replicate from one cell cycle to the next. This may be
the reason why MUTYH, as a genome caretaker, is local-
ized to both the nucleus and the mitochondria [19, 20].
Gene polymorphism and mutations that lead to
MUTYH inactivation have been associated with many
cancers and cancer-associated inflammatory responses
[21–24]. A number of studies have demonstrated that
oxidative DNA strand break, and oxidative stress are sig-
nificantly increased in the mononuclear leukocytes,
serum and synovial fluid from RA patients than healthy
controls [6–9]. The presence of oxidized DNA in joints
has also been linked with arthritis in both mice [25] and
humans [26]. We have previously described the associ-
ation of rheumatoid arthritis (RA) prevalence and two
mutY Homolog (E. coli) (MUTYH) SNPs (rs3219463
and rs3219476) among the Taiwanese population [27]. In
this present study, we increased the sample size of the
cohort and aimed to find out whether the SNPs can alter
the expression of MUTYH in the progression of RA.
Methods
Patient selection
The study subjects included 368 RA patients and 364
healthy subjects, which were recruited from China
Medical University Hospital in Taiwan. Patients with
RA, according to the revised America College of
Rheumatology criteria [28, 29], were enrolled. Nephe-
lometry detected the rheumatoid factor (RF), and values
≧ 30 IU/ml were defined as positive. The gender-age-
matched healthy controls from the general population
were selected by health examination. Blood samples
were collected by venipuncture for genomic DNA isola-
tion. Informed consent was obtained from all partici-
pants, and it was according to the guidelines approved
by the local ethics committee.
Genomic DNA extraction, genotyping and quantitation of
MUTYH copy number
Genomic DNA (gDNA) was prepared from peripheral
blood using the genomic DNA kit from Roche. Polymer-
ase chain reaction was used to identify the MUYTH
rs3219463 polymorphism (Fig. 1). A pre-designed copy
number assay (assay ID: Hs01177408_cn) from Applied
Biosystems was used to quantify MUTYH copy number
by TaqMan®Real-Time PCR. Primer sequences, reaction
components, thermal cycling profiles and identification
of various MUTYH genotypes by restriction enzymatic
digestion and gel electrophoresis are all provided in the
supplementary section.
Quantitative determination of MUTYH in serum
Serum samples were diluted 1/200 in dilution buffer to
be in the range of standard curve and then directly
quantified by enzyme linked immunosorbent assay (Cat
No. 30–7110, ALPCO Diagnostics, USA). The human
MUTYH in the serums samples were bound to mono-
clonal mouse antibodies against human MUTYH, which
were immobilized on the surface of the microtiter plates.
After a washing step, the quantification of bound human
Fig. 1 Map of MUTYH (rs3219463) located within Chromosome 1p34.1 region (45,329,242-45,340,301 bp)
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MUTYH was carried out by adding a rabbit anti-human
MUTYH antibody. Detection of the bound rabbit anti-
body was performed by a peroxidase labeled goat anti-
rabbit antibody. The amount of converted substrate was
directly proportional to the amount of bound human
MUTYH and was photo metrically determined at
450 nm.
Statistical analysis
The genotypic and allelic frequencies of MUTYH
rs3219463 SNP for the RA patients and controls were
compared using the chi-square test. When one cell had
an expected count of <1 or >20% of the cells had an ex-
pected count of < 5, Fisher’s exact test was used. Results
were considered statistically significant when p values
less than 0.05. The odds ratios (OR) were calculated
from the genotypic frequency and allelic frequency with
a 95% confidence interval (95% CI) for the MUTYH
rs3219463 SNP. The statistical analysis was performed
by using SPSS version 11. The Mann–Whitney U test
and Kruskal-Wallis method were used for non-
parametric comparisons, and Student’s t test was used
for parametric comparisons [30].
Results
Genotypic and allelic frequency distributions of MUTYH
rs3219463 SNP among Taiwan’s Han Chinese population
The genotypic and allelic frequency distributions of
rs3219463 SNP in the MUTYH gene were summarized
in Table 1. The Hardy-Weinberg model was used to de-
scribe and predict genotype and allele frequencies in our
study. We observed G allele to be the major allele in the
population, regardless of whether they were in the pa-
tient group or the control group – at rs3219463 SNP
site, the G allele frequencies were 57.6% (424 out of 736)
for patients and 67.2% (489 out of 728) for the controls.
By comparing the genotypic distributions between RA
patients and healthy controls, our data indicated that in-
dividuals who carried GG or GA (G carrier) at
rs3219463 SNP site are statistically significantly at a
lower risk for developing RA (p < 0.0002).
Normal MUTYH CNV in RA patients
Blood leukocytes gDNA samples were available from
227 RA patients and 223 healthy controls. For the
remaining patients and controls, insufficient gDNA was
collected to quantify MUTYH CNV. RA patients were
not associated with abnormal MUTYH CNVs (Table 2).
All patients and controls had 2 copies of the MUTYH
gene present in their genome.
Increased serum level of MUTYH in RA patients
Serum levels of MUTYH were available from 40 RA pa-
tients and 38 healthy controls. For the remaining pa-
tients and controls, insufficient serum was collected to
quantify MUTYH. There was a statistically significant
increase in serum MUTYH concentration among RA
patients (Fig. 2, p < 0.005). The mean MUTYH concen-
trations per milliliter of serum samples from RA patients
and healthy controls are as follows: 21.62 ± 16.53 ng/mL
for RA patients and 19.87 ± 27.47 for healthy controls.
RA patients had 8.8% higher serum MUTYH levels than
their age-, gender- and race-matched healthy controls.
Classification of functional capacity and measurement of
joint changes in RA patients carry risk- and non-risk-
associated MUTYH SNP at rs3219463 site
RA patients can be categorized into four groups based
on their functional capacity assessment. Class 1 patients
can do all the usual activities without help. Class 2 pa-
tients can also do most of the normal activities despite
feeling uncomfortable and thus limiting their mobility of
one or more joints. Class 3 patients can do only a few
tasks, and they are unable to work or they may not take
care of themselves very well. Class 4 patients rely solely
on others to take care them. There were no statistically
significant difference between the RA-risk-associated
group (AA at rs3219463) and the RA-non-risk-associ-
ated group (G carriers at rs3219463) in regards to the
various RA diagnosis classes (Table 3). For the assess-
ment of joint pain and joint stiffness, those RA patients
who are G carriers at rs3219463 are less likely to have
painful joints (Table 3, p < 0.01). We also performed
Table 1 Genotypic and allelic frequency of MUTYH-437 (rs3219463) genetic polymorphism in the RA patients and controls
RA patient Control OR (95% CI) p value
MUTYH-437 (rs3219463) n = 368 (%) n = 364 (%)
AA 54 (14.7) 47 (12.9) 1.80 (1.14-2.84) 6E-06 *
AG 204 (55.4) 145 (39.8) 2.20 (1.60-3.03)
GG 110 (29.9) 172 (47.3) Ref
Allelic frequency
Allele A 312 (42.4) 239 (32.8) 1.51 (1.22-1.86) 0.0002 *
Allele G 424 (57.6) 489 (67.2) Ref
CI confidence interval, OR odds ratio
* Statistically significant
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quantitative joint examinations for our RA patients: the
golden standard 66 swollen/68 tender joint counts
(SJC66/TJC68), the disease activity score in 28 joints
(DAS28), patient global assessment of disease activity
(PtGA) and provider global assessment of disease activ-
ity (PrGA) were investigated among our RA patients. In
our cohort, RA patients who are G carriers at rs3219463
showed statistically significant lower DAS 28 value
(Table 3, p < 0.01) than the ones who carried AA at
rs3219463. In addition, although the data was not statis-
tical significance, those RA patients who were G carriers
at rs3219463 tend to have lower SJC 66, TJC66, PtGA
and PrGA values than those who carry AA at rs3219463
(Table 3).
Discussion
Rheumatoid arthritis (RA) can affect any joint in the
body; the severity varies from person to person. Al-
though the exact causes of RA are unknown, oxidative
stress-induced DNA damage plays a big part. We per-
formed a candidate gene study to investigate the associ-
ation of MUTYH genetic variants with their expression
and disease severity in RA patients. MUTYH was chosen
as a candidate gene because MUTYH polymorphisms
and mutations have been associated with various cancers
and cancer-linked inflammatory responses [21–25]. RA
is characterized by proliferative and invasive synovial fi-
broblasts in the synovium, a cell population with proper-
ties similar to cancer cells [1–5]. We initially tested the
association of four SNPs (rs3219463, rs3219476,
rs3219489 and rs3219493; data not shown) tagging
MUTYH with the incidence of RA in a Taiwan Han
Chinese cohort study. The MUTYH G to A polymorph-
ism at rs3219463 SNP site was identified as a susceptible
allele in relation to RA prevalence. Then, we carried out
several follow-up studies that gave us a more detailed
picture of MUTYH rs3219463 polymorphism and its as-
sociation with RA severity.
The present study extends our earlier publication in
2015 on SNP rs3219463 of MUTYH in Taiwan-Chinese
RA [27]. The sample sizes of RA increased from 192 to
368, and healthy control subjects from 192 to 364. As a
follow-up study, the sample sizes for RA patients and
controls were still relatively small. It would have been
more impactful if the sample size for each group was
greater than 500 samples. Currently, compared with
other studies using Asian individual groups, we have the
biggest sample size RA research. Here, we not only
reporting the characterization of a SNP and potential
copy number variation of MUTYH in rheumatoid arth-
ritis patients, but also the MUTYH protein levels in RA
patient’s serum. Our results indicate a significantly
higher level of MUTYH in patients than in controls. To
our knowledge, this is the first report on MUTYH serum
protein levels in RA patients. And we think that is a very
important information in RA development.
MUTYH is a DNA glycosylase that recognizes and ex-
cises mispaired adenine (A) bases from the DNA back-
bone. Post-translational phosphorylation of MUTYH is
particularly important to grant itself the unique glycosy-
lase activity on A:8-oxo-G and A:G mispairs [18, 31].
This enzyme, found in either nucleus or mitochondria,
predominantly removes A from A:8-oxo-G mispairs
under physiological salt concentrations [17]. As a gen-
ome caretaker that defends genome integrity, MUTYH
is ubiquitously expressed and its activity is directed to
newly synthesized DNA strands [32]. When MUTYH
Table 2 Distribution of MUTYH CNV in the RA patients and controls
RA patient Control OR (95% CI) Chi-Square Fisher’s Exact test
n = 227 (%) n = 223 (%) p value p value
MUTYH CNV
0, 1 or 3 0 0 — — —
2 227 (100%) 223 (100%)
CI confidence interval, OR odds ratio
Fig. 2 The expression level of MUTYH in the serum of RA patients
and controls. p value was calculated by T-Test and Mann–Whitney U
test. * means data is statistically significant
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function is compromised, A:8-oxo-G mispairs on the
newly synthesized DNA are not fixed, CG→AT trans-
version mutations can be generated in the next round of
replication. Accumulations of deleterious mutations in
normal cells ultimately transform them into cancer cells
[33]. MUTYH-associated polyposis (MAP) and colorec-
tal cancer (CRC) are the well-characterized hereditary
conditions related to MUTYH mutations [23]. Indeed,
the BER deficiency associated with MUTYH inactivation
can happen to any cell type and affect any gene. The
MAP tumor spectrum has been expanded to extra-
colonic organs [22, 24, 34–37]. Synovial hyperplasia in
RA is similar to a hyperplastic tumor, together with the
fact that increased oxidative DNA damage and oxidative
stress have been demonstrated in RA patients [6–9], we
believed that MUTYH might have a role to play in RA
pathology.
In this study, we examined the association of rheuma-
toid arthritis prevalence and the MUTYH rs3219463
polymorphism among Taiwan’s Han Chinese population.
MUTYH rs3219463 SNP is located in 3’non-coding re-
gions. This SNP has been linked with higher treatment-
related mortality (TRM) risk and disease relapse in pa-
tients who have undergone allogeneic hematopoietic cell
transplantation (HCT) [38]. Thyagarajan et al. proposed
that lower BER activity can increase damage to normal
tissues, resulting in higher cell death and thus increasing
the risk of TRM [38]. MUTYH composes of localization
sequence, a DNA binding domain, an adenine bind
motif and several interaction domains for APE1, PCNA,
RPA and MSH6 [39]. Various MUTYH isoforms differ
in their 5’ sequence or first exon and they can be
grouped into three categories, namely α, β and γ [40].
Studies have described MUTYH isoforms to differ in
their 5’ sequence which will put them into different
cellular compartments, either nucleus or mitochondria
[19, 20, 40–42]. However, the distribution and functional
statuses of different MUTYH isoforms to the different
subcellular locations in different cell and tissue types are
still not known. Indeed, examples of inter-isoformal
regulation of their functional counterparts are held al-
most everywhere [43, 44]. Therefore, we propose to
proceed further with the study of MUTYH isoform pro-
filing and distribution in association with MUTYH
SNPs.
Our pilot study has attempted to demonstrate whether
MUTYH rs3219463 is associated with RA susceptibility
and disease severity. There was a statistically significant
increase in serum MUTYH concentration among RA
patients. Unfortunately, we lacked samples to monitor
the A/8oxoG base repair. Increased MUTYH expression
may compensate for the loss of functional MUTYH
Table 3 Classification of functional capacity and measurement of joint changes in RA patients
RA patients Chi-Square a
p value
Fisher’s Exact test a
p value
Genotype at rs3219463
G carrier - n (%) AA - n (%)
RA Diagnosis class
I 88 (75.2) 13 (56.5) 0.315 0.199
II 19 (16.2) 6 (26.1)
III 8 (6.8) 3 (13.0)
IV 2 (1.7) 1 (4.3)
RA patients T-Test a
p value
Mann–Whitney U test a
p value
Genotype at rs3219463
G carrier - n (mean ± SD) AA - n (mean ± SD)
MUTYH serum level b 27 (20.98 ± 16.51) 13 (23.07 ± 17.16) 0.714 0.593
Joint pain 135 (31.93 ± 24.33) 28 (45.89 ± 25.46) 0.007 * 0.006 *
Joint stiffness 102 (0.62 ± 0.97) 19 (0.58 ± 0.72) 0.871 0.540
SJC 66 b 142 (1.96 ± 2.69) 26 (2.81 ± 3.18) 0.156 0.250
TJC 68 b 142 (3.83 ± 4.07) 26 (6.69 ± 7.06) 0.055 0.075
DAS 28 133 (3.88 ± 1.2) 25 (4.63 ± 1.23) 0.005 * 0.003 *
PtGA b 135 (39.65 ± 26.72) 27 (50.48 ± 27.82) 0.058 0.052
PrGA b 142 (23.73 ± 17.73) 27 (32.78 ± 23.38) 0.065 0.078
a Nonparametric test
b Mean value is lower in the G carrier / RA-non-risk-associated but data does not reach statistical significance
* Statistically significant
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isoform but further experiments are needed to validate
this hypothesis. Also, a detailed questionnaire evaluated
the joint damage (using joint pain, joint stiffness, SJC66/
TJC68 and DAS28) and the global assessment of disease
activity (using PtGA and PrGA) for our RA patients
[45]. Although there were no statistically significant dif-
ferences between various genotypes regarding RA func-
tion classes, indeed, RA patients who carried a
potentially protective genotype (i.e. G carrier at
rs3219463) had less severe disease symptoms – They
were statistically significant in lower joint pain values
and DAS scores. In addition, although the data did not
reach statistical significance, RA patients who are G car-
riers at rs3219463 tend to have lower SJC 66, TJC66,
PtGA and PrGA values than those who carried AA at
rs3219463. Actually, the evaluation was somehow based
on subjective analysis rather than on rigorous criteria.
Pain level, stiffness level and tenderness level are sub-
jective experiences of individuals. RA is a chronic illness
and many patients with RA will suffer from depression.
We cannot rule out that some patients may report phys-
ical inability and uncomfortableness were caused by psy-
chological factors. In order to get statistically significant
findings, a larger study group will be required to further
verify the relationship between disease phenotypes and
genotypes.
Both RF and anti-CCP are specific markers for RA
because they are produced as part of the process that
leads to joint inflammation in rheumatoid arthritis
[46]. CRP is usually ordered along with ESR, and they
measure how much inflammation is in the body [47].
Although ESR and CRP are not specific tests, flaring
up of these values do indicate that you have inflam-
mation somewhere in your body. The RA patients
who are G carriers at rs3219463 tend to have lower
mean RF and ESR values than the group who carried
AA, but the difference did not reach statistical signifi-
cance, possibly because of the small sample size of
the subgroup analysis. The sample size is closely tied
to statistical power. We have to admit that we have a
small sample size in some subgroups, and sometimes
we cannot get enough blood for both routine and
RA-specific blood tests. Therefore, additional studies
are needed to validate these results by using a larger
cohort of RA patients.
Medications that can reduce joint inflammation, relieve
pain and slow down joint damage are prescribed to treat
or reduce the symptoms of RA. However, some of these
medications can cause serious side effects [48, 49]. In
addition, RA itself can increase the risk of developing cer-
tain cancers and organ dysfunctions in patients. These
complications may affect serum MUTYH levels. We, thus,
carefully documented the drug use patterns of each RA
patient and no serious side effects were observed.
Conclusions
In conclusion, our pilot study showed that RA is associ-
ated with rs3219463 SNP in MUTYH gene and in-
creased serum level of the MUTYH protein. These
findings suggest EGFR is a valuable therapeutic target in
the treatment of RA, and thus, is worthy of further
investigation.
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